General Archive
-
News releases, Ventures fundingLifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
-
News releases, Ventures fundingLifeArc Ventures – strong performance in 2022 & sustained investment in innovation
LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, provides an update on its portfolio.
-
News releases, Ventures fundingLifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
-
Articles & blogs, Ventures fundingAbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
-
News releases, Ventures fundingLifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
-
News releases, Ventures fundingLifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releases, Ventures fundingLifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to…
-
News releases, Ventures fundingLifeArc unveils new strategy and £1.3 billion spend to drive life-changing science
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
-
News releases, Ventures funding
10 new data-driven health companies selected for KQ Labs accelerator programme
10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised mentoring and coaching…
-
News releases, Ventures fundingLifeArc invests in company developing personalised drug and digital combination treatments
LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further…
-
News releases, Ventures fundingThree new Trustees bring more skills and experience to LifeArc
A very warm welcome to three new Trustees who have joined our Board.
-
News releases, Ventures fundingLifeArc invests in Cumulus Neuroscience
Investment part of £6 million funding round led by Dementia Discovery Fund, supported by UK Future Fund